GlassScriptPhysician profile
Lee M Goldman
NPI 1124034376
$7,067.71
in general payments reported to CMS, 2019-2025
25 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $931 · 2021: $2,524 · 2022: $2,104 · 2023: $845 · 2024: $146 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,511.64 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,320.13 | 2020-2023 | Spravato |
| Sunovion Pharmaceuticals INC. | $1,080.78 | 2019-2022 | |
| Alkermes, INC. | $607.04 | 2019-2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $428.58 | 2020-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $321.70 | 2019-2023 | Abilify Mycite |
| Takeda Pharmaceuticals U.S.A., INC. | $299.46 | 2020-2022 | |
| Allergan, INC. | $207.36 | 2019-2020 | |
| Lundbeck LLC | $187.86 | 2019-2024 | Abilify Maintena, Rexulti |
| Merck Sharp & Dohme LLC | $167.96 | 2021-2023 | Belsomra |
| Axsome Therapeutics, INC. | $138.14 | 2022-2024 | Auvelity |
| Vertos Medical, INC. | $128.85 | 2021 | |
| Neurocrine Biosciences, INC. | $114.05 | 2019-2023 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $86.44 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $78.43 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $75.54 | 2020-2021 | |
| Indivior INC. | $61.45 | 2022 | |
| Ironshore Pharmaceuticals INC. | $55.55 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $51.94 | 2020 | |
| Tris Pharma INC | $45.37 | 2023 | Dyanavel Xr |
| Shire North American Group INC | $30.45 | 2019 | |
| Boston Scientific Corporation | $24.31 | 2021 | |
| Eisai INC. | $16.83 | 2022 | |
| Bausch Health US, LLC | $15.53 | 2022 | |
| Corium, LLC | $12.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.